Skip to main content

Table 5 Effect of each parameter on DCR according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter

Univariate

Two-variable

Multivariablea

Variable

Timepoint

Value

p

OR

Lower OR

Upper OR

p

OR

Lower OR

Upper OR

p

OR

Lower OR

Upper OR

Platelets

Basal

 + 10,000

    

0.077

1.027

0.997

1.058

Δ

Ref ≤ 25,000

    

0.043

1.749

1.019

3.001

White blood cell count

Basal

 + 100

    

0.002

1.017

1.006

1.028

Δ

Ref ≤ 1920

    

 < 0.001

4.136

1.927

8.878

0.003

3.422

1.528

7.666

Neutrophils

Basal

 + 100

    

 < 0.001

1.030

1.015

1.044

0.004

1.022

1.007

1.037

Δ

Ref ≤ 310

    

0.021

1.850

1.097

3.120

Lymphocytes

Basal

 + 100

    

0.381

0.987

0.957

1.017

Δ

Ref ≥ − 300

    

0.002

2.621

1.444

4.756

0.074

1.804

0.944

3.446

NL ratio

Basal

 + 1

    

 < 0.001

1.329

1.127

1.568

Δ

Ref ≤ 0.86

    

0.001

2.779

1.503

5.140

PL ratio

Basal

 + 1

    

0.086

1.003

1.000

1.006

Δ

Ref ≤ 22.85

    

0.009

2.022

1.191

3.432

Age

Basal

 + 1

0.879

1.001

0.983

1.020

    

Sex

Basal

Ref F

0.507

0.845

0.514

1.389

    

Number of metastatic sites

Basal

Ref ≥ 3

0.010

0.519

0.316

0.853

    

LDH

Basal

Ref elevated

0.002

0.419

0.243

0.722

    

0.032

0.528

0.295

0.946

  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. OR (odds ratio) values are expressed in terms of risk of non-response
  4. aAfter stepwise selection